BXD-treated DSS colitis mice had higher colonic Nrf2 contents and lower malondialdehyde (an oxidative damage marker) levels, along with reduced inflammatory cytokines, suggesting that its amelioration of colitis was partly achieved through an antioxidant mechanism [36]. The gene discussed is NFE2L2; the disease is colitis.